• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

核医学中乳腺癌的治疗与诊断进展

Theranostic Advances in Breast Cancer in Nuclear Medicine.

机构信息

Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran 1419733141, Iran.

Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz 51368, Iran.

出版信息

Int J Mol Sci. 2021 Apr 27;22(9):4597. doi: 10.3390/ijms22094597.

DOI:10.3390/ijms22094597
PMID:33925632
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8125561/
Abstract

The implication of 'theranostic' refers to targeting an identical receptor for diagnostic and therapeutic purposes, by the same radioligand, simultaneously or separately. In regard to extensive efforts, many considerable theranostic tracers have been developed in recent years. Emerging evidence strongly demonstrates the tendency of nuclear medicine towards therapies based on a diagnosis. This review is focused on the examples of targeted radiopharmaceuticals for the imaging and therapy of breast cancer.

摘要

“治疗诊断学”的含义是指通过相同的放射性配体,同时或分别针对诊断和治疗目的靶向同一受体。鉴于广泛的努力,近年来已经开发出许多相当数量的治疗诊断示踪剂。新出现的证据有力地表明核医学向基于诊断的治疗方法发展的趋势。这篇综述重点介绍了用于乳腺癌成像和治疗的靶向放射性药物的例子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2dab/8125561/5c46c7a867d9/ijms-22-04597-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2dab/8125561/02225a65b133/ijms-22-04597-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2dab/8125561/f3a056f155e2/ijms-22-04597-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2dab/8125561/d97cdb85b4e3/ijms-22-04597-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2dab/8125561/5c46c7a867d9/ijms-22-04597-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2dab/8125561/02225a65b133/ijms-22-04597-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2dab/8125561/f3a056f155e2/ijms-22-04597-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2dab/8125561/d97cdb85b4e3/ijms-22-04597-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2dab/8125561/5c46c7a867d9/ijms-22-04597-g004.jpg

相似文献

1
Theranostic Advances in Breast Cancer in Nuclear Medicine.核医学中乳腺癌的治疗与诊断进展
Int J Mol Sci. 2021 Apr 27;22(9):4597. doi: 10.3390/ijms22094597.
2
Targeted radionuclide therapy: frontiers in theranostics.靶向放射性核素治疗:治疗诊断学的前沿。
Front Biosci (Landmark Ed). 2017 Jun 1;22(10):1750-1759. doi: 10.2741/4569.
3
Radioligand Theranostics in the Management of Neuroendocrine Tumors.放射性配体诊疗学在神经内分泌肿瘤管理中的应用
Pancreas. 2020 May/Jun;49(5):599-603. doi: 10.1097/MPA.0000000000001546.
4
Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.应用治疗诊断偶联物进行放射剂量计算时的物理、化学和生物学意义。
Theranostics. 2022 Jan 1;12(1):232-259. doi: 10.7150/thno.62851. eCollection 2022.
5
Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More.肿瘤临床实践中的诊疗一体化结果:是什么、那又如何、现在该怎么办?此外。
Cancer Biother Radiopharm. 2019 Apr;34(3):135-140. doi: 10.1089/cbr.2019.29006.jht.
6
Navigating the landscape of theranostics in nuclear medicine: current practice and future prospects.核医学治疗诊断学领域的探索:现状与未来前景。
Z Naturforsch C J Biosci. 2024 May 29;79(9-10):235-266. doi: 10.1515/znc-2024-0043. Print 2024 Sep 25.
7
Toward Independent Nuclear Medicine, Molecular Imaging, and Theranostic Programs.迈向独立的核医学、分子影像和诊疗一体化项目。
J Nucl Med. 2019 Aug;60(8):1037. doi: 10.2967/jnumed.119.233627.
8
Theranostic approaches in nuclear medicine: current status and future prospects.核医学中的治疗诊断学方法:现状与未来展望。
Expert Rev Med Devices. 2020 Apr;17(4):331-343. doi: 10.1080/17434440.2020.1741348. Epub 2020 Mar 19.
9
Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology.核医学中的治疗学:精准肿瘤学时代新兴和再现的综合影像与治疗
Radiographics. 2020 Oct;40(6):1715-1740. doi: 10.1148/rg.2020200021.
10
Nuclear Medicine Cancer Care-Current Status and Future Directions for Radiopharmaceutical Diagnostics and Theranostics for Cancer.核医学癌症治疗——癌症放射性药物诊断与诊疗一体化的现状与未来方向
Cancer J. 2024;30(3):140-141. doi: 10.1097/PPO.0000000000000721.

引用本文的文献

1
Radiocobalt theranostic applications: current landscape, challenges, and future directions.放射性钴诊疗应用:现状、挑战与未来方向
Front Nucl Med. 2025 Aug 6;5:1663748. doi: 10.3389/fnume.2025.1663748. eCollection 2025.
2
Signaling pathway dysregulation in breast cancer.乳腺癌中的信号通路失调
Oncotarget. 2025 Mar 13;16:168-201. doi: 10.18632/oncotarget.28701.
3
Diagnostic and Prognostic Accuracy of MiRNAs in Pancreatic Cancer: A Systematic Review and Meta-Analysis.微小RNA在胰腺癌中的诊断和预后准确性:一项系统评价和荟萃分析

本文引用的文献

1
Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review.成纤维细胞活化蛋白(FAP)特异性PET的临床结果及其对放射治疗计划的影响:系统评价
Cancers (Basel). 2020 Sep 15;12(9):2629. doi: 10.3390/cancers12092629.
2
Theranostic Pretargeting Drug Delivery and Imaging Platforms in Cancer Precision Medicine.癌症精准医学中的治疗诊断预靶向给药与成像平台
Front Oncol. 2020 Jul 22;10:1131. doi: 10.3389/fonc.2020.01131. eCollection 2020.
3
A theranostic approach of [Ga]Ga-DOTA.SA.FAPi PET/CT-guided [Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy.
J Cell Mol Med. 2025 Jan;29(2):e70337. doi: 10.1111/jcmm.70337.
4
Improvement of tumor-to-blood ratio of radioimmunoconjugates by poly(ethyleneimine)-containing chelating agent.含聚乙烯亚胺螯合剂对放射免疫缀合物肿瘤与血液比值的改善
Ann Nucl Med. 2025 Apr;39(4):323-333. doi: 10.1007/s12149-024-02003-6. Epub 2024 Nov 25.
5
FAP-Targeted Nanoparticle-based Imaging in Cancer: A Systematic Review.基于靶向FAP纳米颗粒的癌症成像:一项系统综述
J Biomed Phys Eng. 2024 Aug 1;14(4):323-334. doi: 10.31661/jbpe.v0i0.2404-1754. eCollection 2024 Aug.
6
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.与曲妥珠单抗联合帕妥珠单抗和多西他赛用于 HER2 阳性转移性乳腺癌的疗效和安全性:APHINITY 试验的最终分析
Cancer Immunol Immunother. 2024 Aug 6;73(10):197. doi: 10.1007/s00262-024-03782-7.
7
Nucleolin-Targeting AS1411 Aptamer-Conjugated Nanospheres for Targeted Treatment of Glioblastoma.用于胶质母细胞瘤靶向治疗的核仁素靶向AS1411适配体缀合纳米球
Pharmaceutics. 2024 Apr 21;16(4):566. doi: 10.3390/pharmaceutics16040566.
8
Biodistribution Assessment of a Novel Ga-Labeled Radiopharmaceutical in a Cancer Overexpressing CCK2R Mouse Model: Conventional and Radiomics Methods for Analysis.新型镓标记放射性药物在过表达CCK2R的癌症小鼠模型中的生物分布评估:传统及放射组学分析方法
Life (Basel). 2024 Mar 20;14(3):409. doi: 10.3390/life14030409.
9
Optimal Indications of Radioimmunotherapy in Nuclear Medicine: A Mini-Review.放射性免疫治疗在核医学中的最佳适应证:小型综述。
Curr Radiopharm. 2024;17(4):320-329. doi: 10.2174/0118744710295825240308093429.
10
Effectiveness of [Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer.[铜]铜-曲妥珠单抗作为HER2阳性乳腺癌治疗诊断剂的有效性。
Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):2070-2084. doi: 10.1007/s00259-024-06648-3. Epub 2024 Feb 20.
[镓]镓-DOTA.SA.FAPi PET/CT引导下的[镥]镥-DOTA.SA.FAPi放射性核素治疗在一名晚期乳腺癌患者中的诊疗一体化方法:靶向放射性核素治疗的新前沿
Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):942-944. doi: 10.1007/s00259-020-04990-w. Epub 2020 Aug 11.
4
Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies.肽-药物偶联物及其在晚期癌症治疗中的靶点
Front Chem. 2020 Jul 7;8:571. doi: 10.3389/fchem.2020.00571. eCollection 2020.
5
Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA chelators.靶向成纤维细胞活化蛋白(FAP):使用方酸酰胺偶联双功能DOTA和DATA螯合剂的新一代PET放射性示踪剂
EJNMMI Radiopharm Chem. 2020 Jul 29;5(1):19. doi: 10.1186/s41181-020-00102-z.
6
Radiopharmaceutical therapy in cancer: clinical advances and challenges.放射性药物治疗癌症:临床进展与挑战。
Nat Rev Drug Discov. 2020 Sep;19(9):589-608. doi: 10.1038/s41573-020-0073-9. Epub 2020 Jul 29.
7
Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option.前列腺特异性膜抗原靶向治疗在晚期前列腺癌中的应用:一种不断发展的选择。
BJU Int. 2020 Nov;126(5):525-535. doi: 10.1111/bju.15143. Epub 2020 Aug 12.
8
Fibroblast Activation Protein-Targeted PET/CT with Ga-FAPI for Imaging IgG4-Related Disease: Comparison to F-FDG PET/CT.成纤维细胞激活蛋白靶向 PET/CT 联合 Ga-FAPI 对 IgG4 相关疾病的成像:与 F-FDG PET/CT 的比较。
J Nucl Med. 2021 Feb;62(2):266-271. doi: 10.2967/jnumed.120.244723. Epub 2020 Jun 8.
9
Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.神经内分泌肿瘤的治疗学:当前方法和未来挑战概述。
Rev Endocr Metab Disord. 2021 Sep;22(3):581-594. doi: 10.1007/s11154-020-09552-x.
10
PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy.前列腺特异性膜抗原(PSMA)诊疗一体化:PSMA靶向成像与放射性配体治疗现状综述
Cancers (Basel). 2020 May 26;12(6):1367. doi: 10.3390/cancers12061367.